MetLife (NYSE:MET – Get Free Report) had its target price dropped by UBS Group from $96.00 to $95.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the financial services provider’s stock. UBS Group’s price objective points to a potential upside of 25.06% from the company’s current price.
MET has been the subject of several other reports. Keefe, Bruyette & Woods cut their price target on shares of MetLife from $94.00 to $92.00 and set an “outperform” rating for the company in a report on Monday, August 11th. Piper Sandler lowered shares of MetLife from an “overweight” rating to a “neutral” rating and set a $84.00 price target for the company. in a research report on Friday, September 19th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of MetLife in a research report on Wednesday, October 8th. Barclays lifted their target price on shares of MetLife from $93.00 to $98.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Finally, Cowen reissued a “buy” rating on shares of MetLife in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.55.
Get Our Latest Stock Report on MET
MetLife Stock Performance
MetLife (NYSE:MET – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The financial services provider reported $2.34 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.04. The business had revenue of $17.36 billion during the quarter, compared to analyst estimates of $18.64 billion. MetLife had a net margin of 5.83% and a return on equity of 19.88%. MetLife’s revenue was down 5.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.95 EPS. Sell-side analysts expect that MetLife will post 9.65 earnings per share for the current fiscal year.
Hedge Funds Weigh In On MetLife
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Quaker Wealth Management LLC raised its stake in shares of MetLife by 198.2% in the second quarter. Quaker Wealth Management LLC now owns 333 shares of the financial services provider’s stock valued at $27,000 after acquiring an additional 672 shares during the period. Motco boosted its stake in shares of MetLife by 105.5% during the 1st quarter. Motco now owns 413 shares of the financial services provider’s stock worth $33,000 after purchasing an additional 212 shares during the period. Evolution Wealth Management Inc. bought a new position in MetLife during the 2nd quarter valued at about $35,000. Salomon & Ludwin LLC raised its position in MetLife by 95.4% in the 3rd quarter. Salomon & Ludwin LLC now owns 422 shares of the financial services provider’s stock worth $35,000 after purchasing an additional 206 shares during the period. Finally, True Wealth Design LLC lifted its stake in MetLife by 564.1% in the third quarter. True Wealth Design LLC now owns 425 shares of the financial services provider’s stock worth $35,000 after purchasing an additional 361 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.
MetLife Company Profile
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
See Also
- Five stocks we like better than MetLife
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Tempus AI: Volatility Equates to Opportunity in AI Leader
- What is the Hang Seng index?
- Follow the Money: 3 Stocks With High Institutional Ownership
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Can Gold Mining Stocks Shine as the Metals Rally Falters?
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.
